Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 15;19(4):995-1002.
doi: 10.5114/aoms/131089. eCollection 2023.

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases

Marat V Ezhov  1 , Svetlana A Shalnova  2 , Elena B Yarovaya  3 , Vladimir A Kutsenko  3 , Svetlana E Evstifeeva  2 , Victoria A Metelskaya  2 , Oxana M Drapkina  2 , Sergey A Boytsov  1
Affiliations

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases

Marat V Ezhov et al. Arch Med Sci. .

Abstract

Introduction: Lipoprotein(a) (Lp(a)) is recognized as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). The aim of this study was to estimate the distribution of Lp(a) levels in working age adults from the Russian population and to assess its association with ischemic heart disease (IHD), myocardial infarction (MI), stroke, diabetes mellitus (DM), and arterial hypertension (AH).

Material and methods: This substudy of the population-based study "Epidemiology of Cardiovascular Diseases and their Risk Factors in Some Regions of the Russian Federation" (ESSE-RF) included 8461 subjects aged 25-64 years (63.7% women) without lipid-lowering drugs. Atherosclerotic cardiovascular disease was self-reported. Lp(a), apolipoproteins AI and B, and lipid and glucose levels in blood serum were determined.

Results: The prevalence of Lp(a) ≥ 30 mg/dl was 20.5% and 23.0%, and prevalence of Lp(a) ≥ 50 mg/dl was 13.3% and 15.2%, in men and women, respectively. An association of Lp(a) with IHD, MI, and AH, but not with stroke and DM, was shown. A cut-off level of Lp(a) of 9 mg/dl was determined, above which there was increased frequency of MI (by 59.2%, p = 0.02), IHD (by 33.4%, p < 0.001), and AH (by 11.6%, p < 0.001). In the multivariate analysis only the association of Lp(a) with IHD (1.19 (1.01-1.41), p = 0.038) and MI (1.57 (1.06-2.38), p = 0.028) remained significant.

Conclusions: Lipoprotein(a) level ≥ 30 mg/dl was detected in every fifth adult aged 25-64 years. Increased risk of MI and IHD starts at an Lp(a) serum level above 9 mg/dl.

Keywords: distribution; ischemic heart disease; lipoprotein(a); myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Disease distributions according to lipoprotein(a) quintiles AH – arterial hypertension, DM – diabetes mellitus, IHD – ischemic heart disease, MI – myocardial infarction.
Figure 2
Figure 2
Associations of high lipoprotein(a) level (≥ 9 mg/dl) with diseases. Univariate and multivariate analysis
See this image and copyright information in PMC

References

    1. Nordestgaard BG, Chapman MJ, Ray K, et al. . Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53. - PMC - PubMed
    1. Erqou S, Kaptoge S, Perry PL, et al. . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-23. - PMC - PubMed
    1. Clarke R, Peden JF, Hopewell JC, et al. .; PROCARDIS Consortium . Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-28. - PubMed
    1. Katsiki N, Al-Rasadi K, Mikhailidis DP. Lipoprotein (a) and cardiovascular risk: the show must go on. Curr Med Chem 2017; 24: 989-1006. - PubMed
    1. Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Banach M. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery? Prog Cardiovasc Dis 2020; 63: 219-27. - PubMed